Aarti Pharmalabs share news and announcements
NSE: AARTIPHARMBSE: 543748Pharmaceuticals & BiotechnologySmall Cap
Last close ₹820.85down ₹7.95 (0.96%)BSE ₹821.05
Share price at the NSE close on 23 Oct 2026. Previous close ₹828.80.
52-week range of traded prices to 23 Oct 2026
₹585.00Low, 30 Mar 2026₹1,002.40High, 30 Sep 2026
- Next results date: the board meets on 28 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹7,443 Cr705th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 25 May 2026
- 3.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.43%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 7 Aug 2026
- 11.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 25 May 2026
- 0.32
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,02,86043.1% delivered
Aarti Pharmalabs share news and announcements
154 announcements, routine notices left out, newest first. Page 2 of 4.
Sep 2025
18 Sep · Analysts
8 Sep · Legal
Exchange has sought clarification from Aarti Pharmalabs Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
Aug 2025
19 Aug · Corporate action
12 Aug · Disclosure
12 Aug · Board meeting
5 Aug · Analysts
Jul 2025
17 Jul · Rating
Jun 2025
18 Jun · Analysts
May 2025
10 May · Disclosure
Apr 2025
Mar 2025
10 Mar · Disclosure
Feb 2025
5 Feb · Corporate action
5 Feb · Results
Jan 2025
28 Jan · Analysts
18 Jan · Legal
9 Jan · Business
Dec 2024
17 Dec · Business
13 Dec · Board meeting
10 Dec · Analysts
Oct 2024
28 Oct · Board meeting
28 Oct · Board meeting
21 Oct · Analysts
Aug 2024
8 Aug · Management